Harmony Biosciences to Present Dravet Syndrome Drug Data

Encore open-label extension data from Phase 3 ARGUS trial to be presented at 2026 AAN meeting.

Apr. 16, 2026 at 4:23pm

Got story updates? Submit your updates here. ›

An ethereal, ghostly X-ray image revealing the delicate neural structures of a human brain, conceptually representing the advancements in neurological research.The presentation of new data from Harmony Biosciences' clinical trial for a Dravet syndrome treatment could signal progress in addressing this rare and severe form of epilepsy.Plymouth Meeting Today

Harmony Biosciences, a pharmaceutical company, announced that it will present additional data from the open-label extension of its Phase 3 ARGUS clinical trial investigating EPX-100 (clemizole hydrochloride) for the treatment of Dravet syndrome. The data will be presented at the 2026 American Academy of Neurology (AAN) Annual Meeting.

Why it matters

Dravet syndrome is a rare and severe form of epilepsy that begins in infancy. New treatment options are needed to help manage the debilitating symptoms of this condition. The presentation of the ARGUS trial data at the prestigious AAN meeting could signal progress in Harmony's efforts to develop an effective therapy.

The details

The ARGUS trial is an ongoing Phase 3 study evaluating EPX-100, Harmony's investigational drug for Dravet syndrome. The open-label extension data being presented will provide additional insights into the long-term safety and efficacy of the treatment.

  • The 2026 American Academy of Neurology Annual Meeting is scheduled for April 2026.

The players

Harmony Biosciences Holdings, Inc.

A pharmaceutical company focused on developing treatments for rare neurological disorders.

EPX-100 (clemizole hydrochloride)

Harmony's investigational drug for the treatment of Dravet syndrome, a rare and severe form of epilepsy.

ARGUS

Harmony's ongoing Phase 3 clinical trial evaluating EPX-100 for the treatment of Dravet syndrome.

American Academy of Neurology (AAN)

A professional association of neurologists and neuroscience professionals that hosts an annual meeting to share the latest research and advancements in the field of neurology.

Got photos? Submit your photos here. ›

The takeaway

The presentation of the ARGUS trial data at the AAN meeting represents an important milestone in Harmony's efforts to develop a new treatment option for patients living with the debilitating symptoms of Dravet syndrome, a rare and severe form of epilepsy.